Novel targets for HIV-1: Tat-TAR interactions

Information

  • Research Project
  • 6405888
  • ApplicationId
    6405888
  • Core Project Number
    R43AI050390
  • Full Project Number
    1R43AI050390-01
  • Serial Number
    50390
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/10/2001 - 23 years ago
  • Project End Date
    3/31/2002 - 22 years ago
  • Program Officer Name
    MILLER, ROGER H.
  • Budget Start Date
    9/10/2001 - 23 years ago
  • Budget End Date
    3/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/7/2001 - 23 years ago
Organizations

Novel targets for HIV-1: Tat-TAR interactions

DESCRIPTION (Provided by the applicant): The human immunodeficiency virus type-i (HIV-i) is a complex retrovirus that encodes six regulatory proteins, including Tat. The Tat protein is a potent transcriptional activator of the HIV-1 long terminal repeat promoter element. A regulatory element between +1 and +60 in the HIV-1`long terminal repeat which is capable of forming a stable stem-loop structure, designated TAR, is critical for Tat function. In the absence of Tat, RNA polymerase II (pol II) terminates transcription prematurely. Tat-TAR interactions help convert pol II interactions with the RNA template into efficiently produced full-length viral transcripts. We have recently demonstrated that combinatorial libraries composed of tripeptides contained molecules that not only bound to TAR but also inhibited Tat interaction with Tar and subsequent LTR directed transcription was reduced in cell culture. The goal of the proposed research is the discovery of low molecular weight non-peptide compounds that inhibit HIV replication by binding to the TAR RNA element. The success of this research would open the door to new opportunities in the discovery of drugs which bind to discrete RNA structures with possible applications for diseases such as cancer and aids. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    140000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:140000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PTC THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH PLAINFIELD
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07080
  • Organization District
    UNITED STATES